TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- E-Motion Medical Ltd. announced today it has received CE Mark approval for its lead product, the E-Motion System™, providing stimulation therapy that restores the natural motor function of the digestive system for patients with acute gastrointestinal dysmotility (GID). Acute GID is common in neurological, trauma, surgical, geriatric and severe diabetic patients. It manifests itself as reduction in, or lack of, motility in the digestive system, and leads to increased risk of complications and longer recovery time.
To restore motility to the digestive system, the E-Motion System™ delivers unique patterns of electrical stimulation to the esophagus. The stimulation is applied to the esophagus using the Company's proprietary applicator, the E-Motion Tube™, which is easily placed by the nursing staff in the same manner as a regular feeding tube. The applied stimulation generates contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract.
To date, the E-Motion System was tested on approximately 230 people in four clinical trials, conducted in 12 hospitals in Europe and Canada. The latest trial was a randomized, sham-controlled, double-blinded trial, including 155 patients. This study was recently completed, demonstrating that the treatment provided by the E-Motion System promotes gastric motility, reduces risk of aspirations, and speeds up recovery.
"There is currently no adequate solution for the widespread problem of acute digestive dysmotility. Our technology provides a new and first of its kind therapy to promote the physical function of the digestive system, and consequently improve outcomes and lower financial burden on the healthcare system," said Amichay H. Gross, Co-Founder and CEO of E-Motion Medical. "The CE Mark is an important milestone for E-Motion Medical, as it will allow commercial access to hospitals across Europe."
About The E-Motion System™
The E-Motion System is a novel stimulation therapy for patients with acute digestive dysmotility. The system is based on the Company's unique and patented technology that creates localized contractions of the muscle in numerous locations along the esophageal body, in a pattern that imitates the natural lower esophageal swallowing motions in a healthy person. This has several positive effects, including pushing down gastric content and preventing it from refluxing up the esophagus, increased gastric emptying, and promotion of the feeds to the intestine for it to be digested and absorbed as nutrients that the critically ill body needs for healing.
About Gastrointestinal Dysmotility
Many millions of patients suffer from gastrointestinal dysmotility (GID), leading to increased risk of complications and longer recovery time. It is common in neurological, trauma, surgical, geriatric and also severe diabetic patients. In addition, gut motility has been shown to have correlation to other physical function in the body, including that of the diaphragm and the lungs, and other systems required for patient recovery. To date, GID lacks adequate treatment.
About E-Motion Medical
Founded in 2011, E-Motion Medical developed the first non-pharmaceutical therapy for restoring the natural motor function of the digestive system for people suffering from digestive dysmotility. The CE Mark approved E-Motion System was successfully tested in clinical trials in Europe and Canada. For additional information, please visit http://emotionmed.com.
Amichay H. Gross, CEO
Tsipi Haitovsky, Global Media Liaison
SOURCE E-Motion Medical Ltd.